Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Adriforant

Copy Product Info
😃Good
Catalog No. T68280Cas No. 943057-12-3
Alias ZPL-3893797, ZPL3893797, ZPL-389, ZPL389, PF-3893787, PF3893787

Adriforant (PF-3893787,ZPL-3893797) is a competitive H4 (histamine receptor 4) antagonist that antagonizes histamine-induced phosphorylation of ERK, normalizes histamine-induced transcriptional changes in mast cells and reduces histamine-dependent Ca2+ fluxes in neurons, which alleviates itching and skin inflammation in mice

Adriforant

Adriforant

Copy Product Info
😃Good
Purity: 99.84%
Catalog No. T68280Alias ZPL-3893797, ZPL3893797, ZPL-389, ZPL389, PF-3893787, PF3893787Cas No. 943057-12-3
Adriforant (PF-3893787,ZPL-3893797) is a competitive H4 (histamine receptor 4) antagonist that antagonizes histamine-induced phosphorylation of ERK, normalizes histamine-induced transcriptional changes in mast cells and reduces histamine-dependent Ca2+ fluxes in neurons, which alleviates itching and skin inflammation in mice
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$293-In Stock
5 mg$722-In Stock
10 mg$987-In Stock
25 mg$1,520-In Stock
50 mg$1,980-In Stock
100 mg$2,500-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.84%
Appearance:Viscous
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Adriforant (PF-3893787,ZPL-3893797) is a competitive H4 (histamine receptor 4) antagonist that antagonizes histamine-induced phosphorylation of ERK, normalizes histamine-induced transcriptional changes in mast cells and reduces histamine-dependent Ca2+ fluxes in neurons, which alleviates itching and skin inflammation in mice
Targets&IC50
Eosinophil cell shape change:0.65  nM, Actin polymerization (eosinophils):1.3  nM, CD11b expression (eosinophils):4.9  nM
In vitro
Adriforant was tested in various human eosinophil functional assays, including cell shape change (IC₅₀ = 0.65 nM), CD11b expression (IC₅₀ = 4.9 nM), and actin polymerization (IC₅₀ = 1.3 nM). In a whole blood granulocyte assay (GAFS), Adriforant fully blocked imetit-induced responses at 30 nM. The binding affinity (Ki) for human H4R was 2.4 nM, with a functional Ki of 1.56 nM, indicating potent and selective H4R antagonism[1].
In vivo
Adriforant was administered orally (5 mg/kg, p.o.) and intravenously (1 mg/kg, i.v.) in rats, showing good pharmacokinetics (T₁/₂ = 7 h, F = 62%). In dogs, oral dosing (10 mg/kg, p.o.) also showed favorable exposure (T₁/₂ = 24 h, F = 39%). In 7-day repeat-dose toxicity studies in rats and monkeys, no adverse effects were observed at free plasma concentrations up to 187–240× the predicted minimum human efficacious level[1].
SynonymsZPL-3893797, ZPL3893797, ZPL-389, ZPL389, PF-3893787, PF3893787
Chemical Properties
Molecular Weight262.35
FormulaC13H22N6
Cas No.943057-12-3
SmilesN(C)[C@H]1CN(CC1)C=2C=C(NCC3CC3)N=C(N)N2
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Adriforant | purchase Adriforant | Adriforant cost | order Adriforant | Adriforant chemical structure | Adriforant in vivo | Adriforant in vitro | Adriforant formula | Adriforant molecular weight